180 Life Sciences ROCE
Quel est le ROCE de 180 Life Sciences?
Le ROCE de 180 Life Sciences Corp. est 14,186.55%
Quelle est la définition de ROCE?
Le retour sur capital utilisé (ROCE) est un ratio financier qui mesure la rentabilité d'une entreprise et l'efficacité avec laquelle son capital est utilisé.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE des entreprises dans Health Care secteur sur NASDAQ par rapport à 180 Life Sciences
Que fait 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Entreprises avec roce similaire à 180 Life Sciences
- Blue Apron Inc a ROCE de 5,016.13%
- ParkerVision a ROCE de 5,589.92%
- Asensus Surgical Inc a ROCE de 5,861.92%
- Whiting USA Trust II a ROCE de 7,251.43%
- Astra a ROCE de 7,618.05%
- Kalo Gold a ROCE de 8,333.61%
- 180 Life Sciences a ROCE de 14,186.55%
- Ideanomics Inc a ROCE de 29,881.71%
- Internet Gold - Golden Lines a ROCE de 31,538.46%
- Predictiv Ai Inc a ROCE de 33,476.12%
- T2 Biosystems Inc a ROCE de 56,826.92%
- AMBG a ROCE de 145,496.28%
- Woluwe Shopping Center a ROCE de 520,618,500.00%